Neuroprotective Effects of a Cholecystokinin Analogue in the 1-Methyl-4-Phenyl-1,2,3,6-Tetrahydropyridine Parkinson’s Disease Mouse Model

Parkinson’s disease (PD) is a chronic neurodegenerative disease. Type 2 diabetes mellitus (T2DM) has been identified as a risk factor for PD. Drugs originally developed for T2DM treatment such as liraglutide have shown neuroprotective effects in mouse models of PD. Cholecystokinin (CCK) is a peptide...

Descripción completa

Detalles Bibliográficos
Autores principales: Zhang, Zijuan, Li, Hai, Su, Yunfang, Ma, Jinlian, Yuan, Ye, Yu, Ziyang, Shi, Ming, Shao, Simai, Zhang, Zhenqiang, Hölscher, Christian
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2022
Materias:
Neuroscience
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8964967/
https://www.ncbi.nlm.nih.gov/pubmed/35368248
http://dx.doi.org/10.3389/fnins.2022.814430

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8964967/
https://www.ncbi.nlm.nih.gov/pubmed/35368248
http://dx.doi.org/10.3389/fnins.2022.814430

Ejemplares similares